The cancer diagnostics company is hours away from losing funding for its tests through the US Medicare system.
UPDATE: Dual-listed cinema software provider’s 19.9% investor has called a shareholder meeting to vote on board changes.
The milk processor has less than a year’s grace to turn its business around and secure its milk supplies.
CEO Anna Scott says the exercise cost ‘a modest sum’.
Listed pharma company signed exclusive licensing deal for intravenous form of its pain relief medicine in world’s second-largest pharma market.
‘We’re not denying this is probably one of the toughest retail environments that we can all remember,’ CEO says.
Restaurant group will also mop up smaller shareholders as it looks to beef up share price.
Infant formula marketer says acquisition talks unlikely to be behind share price surge.
Payment of 20c a kg available to suppliers still on board next May.
‘I don’t want to become an expert in this area, that’s for sure,’ CEO says about patent dispute.